FGFR2 Gene Fusion/Rearrangement

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Elevar Therapeutics
Elevar TherapeuticsKorea - Seoul
1 program
1
LirafugratinibPhase 2Small Molecule1 trial
Active Trials
NCT07359820Not Yet Recruiting30Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2026
2027
2028
Elevar TherapeuticsLirafugratinib

Clinical Trials (1)

Total enrollment: 30 patients across 1 trials

NCT07359820Elevar TherapeuticsLirafugratinib

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Start: Feb 2026Est. completion: Dec 202830 patients
Phase 2Not Yet Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space